Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
25 results
- D3.196 - Efficacy of sublingual immunotherapy in children with allergic rhinitis
D3.193 - Impact of subcutaneous allergen immunotherapy on autoimmune disease development or exacerbations: a cross-sectional study
D3.194 - Renewal’s analysis of liquid sublingual immunotherapy (SLIT) treatments using iPUMP: SPEED study, a Real-Life study
D3.195 - Reasons for declining venom immunotherapy and its burden on patients' daily lives
D3.197 - When is molecular testing necessary? Rethinking allergy diagnostics for Dermatophagoides pteronyssinus
D3.198 - Hymenoptera Venom Allergy: A Case Report on Safe Discontinuation After Five Years of Venom Immunotherapy
D3.202 - Allergen-Specific Immunotherapy Is Still Rarely Used: Results of an Online Survey in Lithuania
D3.203 - Yeast surface display as platform for generation of nanobodies to single allergens and allergen extracts
D3.204 - Elevated Tryptase Levels in a Severe Asthmatic Patient Undergoing SCIT for Birch: Implications for Monitoring and Personalized Treatment
D3.205 - Online Education Increases Clinician Knowledge and Confidence in Utilizing Allergen Immunotherapy for Respiratory Allergic Disease
D2.115 - Association of chemokine levels with types of reactions after alcohol consumption in patients with nonsteroidal anti-inflammatory drugs exacerbated respiratory disease (N-ERD)
D2.116 - Occupational asthma due to Chinese yeast, Yeast and Peptone
D2.117 - The interaction of exposure to air pollutants and inflammatory markers on lung function and asthma symptoms in asthmatic patients
D2.118 - Eosinophilic Esophagitis and Atopy: A Shared Mechanism of Type 2 Inflammation
D2.119 - Real-life experience in eosinophilic granulomatosis with polyangiitis (EGPA) after 12 months with mepolizumab 300mg in specialized autoimmune and asthma units in an Universitary Hospital
D2.122 - Dupilumab-Induced Diffuse Eosinophilic Drug Rash with Hypereosinophilia in a Patient with Idiopathic Pulmonary Fibrosis and Severe Asthma Exacerbation: A First Case Report
D2.123 - The impact of wartime environmental change on the frequency of asthma diagnoses
D2.124 - Clinical Characteristics and Predictors in Patients with Difficult-to-Treat Asthma
D2.125 - Occupational asthma in hairdressers due to hair dyes containing para-amino compounds
D2.127 - The bacterial lysate OM-85 mitigates HDM-induced allergic inflammation through the airway epithelial cell- macrophage crosstalk
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download